An interventional study of NHF high and NHF low in Respiratory Distress Syndrome, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 2 sites in 2 countries. Open to participants aged 23 Weeks to 31 Weeks. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 10th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 with no phase, and was the 47th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany
Ages 18+
BioAegis Therapeutics Inc. · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
University Hospital Tuebingen · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 36 more countries
Ages 18+
CytoSorbents, Inc · Sites in Germany, Austria, Italy and 3 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 23 Weeks to 31 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 7
First in 2003; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 150 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 114 across the 26 interventional studies, 132 across the 21 observational. Of the 28 that completed or were terminated, 4 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 48 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Distress Syndrome with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05947955BioAegis Therapeutics Inc.Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Premature babies often need help breathing for a longer period of time. Traditionally, this is done with a breathing aid called NCPAP (nasal continuous positive airway pressure). This treatment is safe and effective, but it is very time-consuming and can sometimes have side effects. In the present research project, the investigators want to find out whether another type of breathing aid called NHF (nasal high flow therapy) is just as effective for stable premature babies. The investigators suspect that NHF is just as effective, but easier to use and more comfortable.
This is a multi center parallel group three arm randomized controlled clinical trial investigating cardiorespiratory stability in stable preterm infants receiving NHF.
Currently, NCPAP remains the gold standard for administration of prolonged non-invasive ventilatory support in very preterm infants. NHF is a promising method for tailored, less invasive long-term ventilatory support for preterm infants. If ventilatory support with NHF is similarly effective to conventional NCPAP in stable preterm infants, clinicians are likely to adopt this method for widespread clinical use because of its improved comfort and potential other benefits. Primary aim of this trial is to examine cardiorespiratory stability in preterm infants treated with two commonly used NHF flowrates (Interventional group 1 and 2) in comparison to NCPAP (Comparator). Secondary aim is to examine potential comfort-related beneficial effects of NHF.
Inclusion Criteria:
Inclusion if all apply.
Stable on NCPAP 6 cm H2O for ≥ 24 hours, defined as:
Exclusion Criteria:
Exclusion if any applies.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nasal high flow therapy 8L/min
Other: NHF high
Nasal high flow therapy 6L/min
Other: NHF low
Nasal continuous positive airway pressure 6 cm H20
Other: NCPAP
Nasal high flow therapy 8L/min.
Nasal high flow therapy 6L/min.
Nasal continuous positive airway pressure 6 cm H20
Treatment failure
Treatment failure is a composite outcome defined as meeting one of the following treatment failure criteria within 24 hours of starting of intervention: 1. \>2 apneas with concomitant bradycardias (\<100/min) per hour for \> 1 hour or 2. FiO2 \> 0.3 consistently for \> 1 hour or 3. Significant chest recessions (Silverman Score ≥ 5) for \> 1 hour or 4. Respiratory rate \> 60/min consistently for \> 1 hour or 5. Any need for intermittent positive pressure ventilation The presence of "Treatment failure" within 24 hours of starting of intervention will be documented (dichotomous outcome; yes/no).
Time frame: 24 hours
Apneas and bradycardias
The total frequency of apneas and bradycardias (\<100/min) within 24 hours of starting of intervention will be documented.
Time frame: 24 hours
Respiratory rate (RR)
The mean RR within 24 hours of starting of intervention will be documented.
Time frame: 24 hours
Heart rate (HR)
The mean HR within 24 hours of starting of intervention will be documented.
Time frame: 24 hours
Oxygen saturation (SpO2) and fraction of inspired oxygen (FiO2)
The mean SpO2/FiO2 ratio within 24 hours of starting of intervention will be documented.
Time frame: 24 hours
Frequency of any treatment failure
Treatment failure is a composite outcome (see "Outcome 1"). The frequency of any treatment failure during the duration of the study will be documented.
Time frame: Individual study duration: estimated to be between a minimum of 7 days to an (estimated) maximum of 10 weeks.
Rescue NCPAP
Rescue NCPAP is defined as NCPAP \>6 cm H2O. The frequency of need for Rescue NCPAP during the duration of the study will be collected.
Time frame: Individual study duration: estimated to be between 7 days to 10 weeks.
Postmenstrual age (PMA) off positive pressure support
The investigators will document the PMA when the infant is off positive pressure support.
Time frame: Estimated to be at a PMA of approximately 29 to 34 weeks.
Postmenstrual age (PMA) off FiO2 > 0.21
The investigators will document the PMA when the infant is off FiO2 \> 0.21
Time frame: Estimated to be at a PMA between approximately 28 to 34 weeks.
Postmenstrual age (PMA) at discharge
The investigators will document the PMA when the infant is being discharged from the hospital.
Time frame: Estimated to be at a PMA of approximately 38-40 weeks.
Cerebral oxygen saturation (cRSO2) 1 hour before until 3 hours after start of the intervention
The cerebral oxygen saturation (cRSO2) in \[%\] 1 hour before until 3 hours after start of the intervention will be measured by using Near-infrared spectroscopy (NIRS).
Time frame: 4 hours
Time spent <55% cRSO2 1 hour before until 3 hours after start of the intervention
The time spent \<55% cRSO2 in \[min\] 1 hour before until 3 hours after start of the intervention will be measured by using Near-infrared spectroscopy (NIRS).
Time frame: 4 hours
Cerebral oxygen saturation (cRSO2) 1 hour before until 3 hours after cessation of the intervention
The cerebral oxygen saturation (cRSO2) in \[%\] 1 hour before until 3 hours after cessation of the intervention will be measured by using Near-infrared spectroscopy (NIRS).
Time frame: 4 hours
Time spent <55% cRSO2 1 hour before until 3 hours after cessation of the intervention
The time spent \<55% cRSO2 in \[min\] 1 hour before until 3 hours after cessation of the intervention will be measured by using Near-infrared spectroscopy (NIRS).
Time frame: 4 hours
Change in end-expiratory lung impedance (ΔEELI)
The change Δ in end-expiratory lung impedance (ΔEELI) will be measured using electrical impedance tomography (EIT) at 9 different timepoints during the first 48 hours after starting of intervention. One measurement will last 6 minutes. The measurements will take place: * within 30 minutes before starting of intervention (baseline measurement) * 3 minutes before until 3 minutes after starting of intervention * within 30 minutes after starting of intervention * 2, 6, 12, 24, 36, and 48 hours after starting of intervention
Time frame: 48 hours
Change in global inhomogeneity (ΔGI) index
The change Δ in global inhomogeneity (ΔGI) index will be measured using electrical impedance tomography (EIT) at 9 different timepoints during the first 48 hours after starting of intervention. One measurement will last 6 minutes. The measurements will take place: * within 30 minutes before starting of intervention (baseline measurement) * 3 minutes before until 3 minutes after starting of intervention * within 30 minutes after starting of intervention * 2, 6, 12, 24, 36, and 48 hours after starting of intervention
Time frame: 48 hours
Change in variability of tidal volume (ΔTV)
The change Δ in variability of tidal volume (ΔTV) will be measured using electrical impedance tomography (EIT) at 9 different timepoints during the first 48 hours after starting of intervention. One measurement will last 6 minutes. The measurements will take place: * within 30 minutes before starting of intervention (baseline measurement) * 3 minutes before until 3 minutes after starting of intervention * within 30 minutes after starting of intervention * 2, 6, 12, 24, 36, and 48 hours after starting of intervention
Time frame: 48 hours
Change in ratio of tidal volume anterior/posterior (ΔRatio TV ap)
The change Δ in ratio of tidal volume anterior/posterior (ΔRatio TV ap) will be measured using electrical impedance tomography (EIT) at 9 different timepoints during the first 48 hours after starting of intervention. One measurement will last 6 minutes. The measurements will take place: * within 30 minutes before starting of intervention (baseline measurement) * 3 minutes before until 3 minutes after starting of intervention * within 30 minutes after starting of intervention * 2, 6, 12, 24, 36, and 48 hours after starting of intervention
Time frame: 48 hours
Incidence of Bronchopulmonary dysplasia (BPD)
The incidence with specification of severity of BPD at 36 weeks PMA will be documented. BPD is a form of chronic lung disease (CLD). BPD is classified into 3 levels of severity according to the internationally used definition of Jobe and Bancalari (1). FiO2 \>0.21 for ≥ 28 days and 1. Breathing room air (mild) 2. FiO2 \<0.3 (moderate) 3. FiO2 ≥ 0.3 and/or positive pressure support (severe) (1) Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-9.
Time frame: At 36 weeks PMA
Urinary cortisol
A 24-hour-urine-sample will be collected on the third study day. The urinary production rates of cortisol and the most important metabolites will be documented as an indicator for infant stress.
Time frame: 24 hours
COMFORTneo score
The COMFORTneo score will be documented on the third, fourth and fifth study day. The score measures comfort and chronic pain by observation.
Time frame: 72 hours
Revised Bernese Pain Scale for Neonates (BSN-R) score
The BSN-R score will be documented on the third, fourth and fifth study day. The score measures pain.
Time frame: 72 hours
Parental assessment of comfort
The parents will be asked 3 predefined questions concerning their infants' comfort on the on the third, fourth and fifth study day.
Time frame: 72 hours
NASA Task Load Index (NASA-TLX)
The NASA-TLX will be filled out by the participants' nurses on the third, fourth and fifth study day. The NASA-TLX is a questionnaire that measures workload.
Time frame: 72 hours
Nasal trauma score
The nasal trauma score is assessed according to internal standard guidelines in case of a present nasal trauma. The highest respective score and time of assessment will be documented on the participant CRF at 36 weeks PMA. Measuring nasal trauma using the Nasal trauma score takes approximately 20 seconds.
Time frame: Individual study duration: estimated to be between 7 days to 10 weeks.
Behavioral Sleep stage classification for Preterm Infants (BeSSPI)
Sleep-wake cycles as determined by the BeSSPI on the fourth study day will be documented. The BeSSPI identifies sleep stages by observation and takes approximately 2.5 hours.
Time frame: 24 hours
Parental Bonding Questionnaire (PBQ)
The score of the PBQ will be documented at 36 weeks PMA. The PBQ investigates infant-parental bonding.
Time frame: At 36 weeks PMA
Age at initiating breastfeeds
The postmenstrual age (PMA) at initiating breastfeeds will be documented. This refers to the PMA at which the first successful breastfeeding attempt takes place.
Time frame: Estimated to be between 30-34 weeks PMA.
Age at reaching full breastfeeds
The postmenstrual age (PMA) at reaching full breastfeeds will be documented. This corresponds to 100% nutrition per breastfeeds for 24 consecutive hours.
Time frame: Estimated to be between 34-40 weeks PMA.
Weight
The weight in \[g\] at 36 weeks postmenstrual age (PMA) will be documented.
Time frame: At 36 weeks PMA
Head circumference
The head circumference in \[cm\] at 36 weeks postmenstrual age (PMA) will be documented.
Time frame: At 36 weeks PMA
Plan to share: No
Started Jul 2023 (actual). Primary completion is estimated for Dec 2025, 29 months after the start.
Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 29 months is above that.
Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Insel Gruppe AG, University Hospital Bern →